Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 46

Results For "NAL"

8058 News Found

Krsnaa Diagnostics operationalized four diagnostics centres for Punjab Govt
Clinical Trials | January 19, 2023

Krsnaa Diagnostics operationalized four diagnostics centres for Punjab Govt

The company has operationalized diagnostics center at Ferozepur, Gurdaspur, Nawanshahr, and Kapurthala in Punjab.


Dozee partners British International Investment to transform public healthcare in India
Healthcare | January 13, 2023

Dozee partners British International Investment to transform public healthcare in India

The goal of Dozee’s partnership with BII is to improve access to healthcare across India and alleviate the workload of healthcare workers, reduce nurse burnout and fatigue in hospital wards


Zydus receives final approval and 180 days shared exclusivity from USFDA for Brexpiprazole tablets
Drug Approval | January 13, 2023

Zydus receives final approval and 180 days shared exclusivity from USFDA for Brexpiprazole tablets

Brexpiprazole is an atypical antipsychotic indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults


Moderna and CytomX partner for mRNA-based conditnionally activated therapeutics
News | January 11, 2023

Moderna and CytomX partner for mRNA-based conditnionally activated therapeutics

Collaboration to generate and develop therapeutics for oncology and non-oncology conditions


Zydus receives final approval from the USFDA for Febuxostat Tablets
Drug Approval | January 10, 2023

Zydus receives final approval from the USFDA for Febuxostat Tablets

Febuxostat tablets had annual sales of USD 32 million in the United States according to IQVIA data (IQVIA MAT Sept. 2022).


Alembic receives USFDA final approval for Fesoterodine Fumarate Extended-Release Tablets
Drug Approval | January 07, 2023

Alembic receives USFDA final approval for Fesoterodine Fumarate Extended-Release Tablets

Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, have an estimated market size of US$ 177 million for twelve months ending Sep 2022


‘SMART’ program for Ayurveda professionals to boost research in Ayurveda
Policy | January 03, 2023

‘SMART’ program for Ayurveda professionals to boost research in Ayurveda

The proposed initiative is conceptualised with an objective to identify, support, and promote innovative research ideas in healthcare research


Mandaviya reviews arrangements for screening and testing of international passengers
Policy | January 03, 2023

Mandaviya reviews arrangements for screening and testing of international passengers

Passengers arriving from 6 high-risk countries are now mandatorily required to upload their negative RT-PCR test


InnoCare get approval of Tafasitamab with Lenalidomide for the treatment of refractory diffuse large B-Cell lymphoma in Hong Kong
Drug Approval | December 31, 2022

InnoCare get approval of Tafasitamab with Lenalidomide for the treatment of refractory diffuse large B-Cell lymphoma in Hong Kong

Tafasitamab is conditionally approved by both the U.S. Food and Drug Administration and European Medicines Agency


Zydus receives final approval from USFDA for Triazolam Tablets
Drug Approval | December 31, 2022

Zydus receives final approval from USFDA for Triazolam Tablets

Triazolam tablets are used on a short-term basis to treat insomnia (difficulty falling asleep or staying asleep)